Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2010-03-08Clinical Trial Update: Effect of Food on the Pharmacokinetics of Oral Treprostinil [Phase 1]
Phase 1 trial evaluating how food intake affects the pharmacokinetics of oral treprostinil in patients with pulmonary arterial hypertension …
-
CLINICAL_TRIALS trial_result · 2010-03-08Clinical Trial Update: ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH) [Phase 3]
Phase 3 trial update on ambrisentan (Letairis) in adults with moderate to severe pulmonary arterial hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2010-03-08Clinical Trial Update: Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil [Phase 1]
A Phase 1 study assessing the impact of esomeprazole on the pharmacokinetics of oral treprostinil has been completed.
-
FDA approval · 2010-02-19FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for TRACLEER (bosentan) from Actelion Pharmaceuticals US, resulting in a labeling update. Bosent…
-
EMA withdrawal · 2010-02-19United Therapeutics Europe Ltd withdraws its marketing authorisation application for Tyvaso
United Therapeutics Europe Ltd has withdrawn its marketing authorization application for Tyvaso with the European Medicines Agency.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2010-02-15Clinical Trial Update: Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension [Phase 2]
The Phase 2 pediatric trial evaluating inhaled iloprost for pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2010-02-12Clinical Trial Update: The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension [Phase 3]
Phase 3 trial evaluating the efficacy and safety of vardenafil in treating pulmonary arterial hypertension. The study status is completed.
-
FDA approval · 2010-01-08FDA Approved: REMODULIN — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for REMODULIN (treprostinil) submitted by United Therapeutics Corporation.
-
FDA approval · 2009-11-18FDA Approved: REVATIO — Original Application (Viatris Specialty LLC)
The FDA approved Revatio (sildenafil citrate) via an original application by Viatris Specialty LLC for the treatment of pulmonary arterial h…
-
CLINICAL_TRIALS withdrawal · 2009-11-13Clinical Trial Update: Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension [Phase 3]
A Phase 3 study evaluating the addition of sildenafil to bosentan therapy for pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2009-11-10Clinical Trial Update: Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension [Phase 2]
Phase 2 trial evaluating the efficacy, safety and pharmacokinetics of GSK1325760A in pulmonary arterial hypertension has completed, with res…
-
FDA approval · 2009-08-07FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) from Actelion Pharmaceuticals US, Inc., updating labeling and/or indications…
-
FDA approval · 2009-08-05FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) submitted by Gilead Sciences, Inc.
-
FDA approval · 2009-07-30FDA Approved: TYVASO — Original Application (United Therapeutics Corporation)
The FDA approved TYVASO (treprostinil) under its Original Application from United Therapeutics Corporation for the treatment of pulmonary ar…
-
CLINICAL_TRIALS trial_result · 2009-07-21Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension. [Phase 3]
A Phase 3 randomized, double-blind, placebo-controlled study evaluated sildenafil in children with pulmonary arterial hypertension; trial co…
-
FDA approval · 2009-07-01FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) submitted by Gilead Sciences.
-
FDA approval · 2009-05-29FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
FDA approves a supplemental application for LETAIRIS (ambrisentan) filed by Gilead Sciences, Inc., authorizing a change to its labeling.
-
FDA approval · 2009-05-22FDA Approved: ADCIRCA — Original Application (United Therapeutics Corporation)
FDA approved Adcirca (tadalafil) under the original application from United Therapeutics for the treatment of pulmonary arterial hypertensio…
-
FDA approval · 2009-05-07FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
FDA approved a supplemental application for Revatio (sildenafil citrate) submitted by Pfizer Laboratories. The action relates to regulatory …
-
CLINICAL_TRIALS trial_result · 2009-04-17Clinical Trial Update: Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
A post-marketing surveillance study evaluating Ventavis (iloprost) in Chinese patients with pulmonary arterial hypertension has been complet…
-
CLINICAL_TRIALS trial_result · 2009-04-16Clinical Trial Update: Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 trial evaluating BSF 208075 on exercise capacity in patients with pulmonary arterial hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2009-04-16Clinical Trial Update: Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. [Phase 3]
Phase 3 trial evaluating ambrisentan in pulmonary arterial hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2009-04-16Clinical Trial Update: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. [Phase 3]
A Phase 3 randomized, double-blind, placebo-controlled trial evaluating ambrisentan for pulmonary arterial hypertension has completed; the u…
-
CLINICAL_TRIALS trial_result · 2009-03-18Clinical Trial Update: A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease [Phase 3]
A Phase 3 clinical trial evaluating bosentan for exercise-induced pulmonary arterial hypertension in patients with connective tissue disease…
-
FDA approval · 2009-03-17FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) submitted by Actelion Pharmaceuticals US, Inc., resulting in an approval tha…